RAPT vs. CGON

Last updated Apr 1, 2026

Compare and contrast key facts about RAPT Therapeutics, Inc. (RAPT) and CG Oncology, Inc (CGON).

Performance

RAPT vs. CGON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in RAPT Therapeutics, Inc. (RAPT) and CG Oncology, Inc (CGON). The values are adjusted to include any dividend payments, if applicable.

RAPT vs. CGON - Yearly Performance Comparison

	2026 (YTD)	2025	2024
RAPT RAPT Therapeutics, Inc.	71.30%	167.96%	-93.40%
CGON CG Oncology, Inc	63.01%	44.77%	-22.84%

Fundamentals

Market Cap RAPT : $1.56B CGON : $5.23B
EPS RAPT : -$3.92 CGON : -$2.10
PB Ratio RAPT : 10.29 CGON : 6.95
Total Revenue (TTM) RAPT : $0.00 CGON : $4.04M
Gross Profit (TTM) RAPT : -$200.00K CGON : -$607.00K
EBITDA (TTM) RAPT : -$108.01M CGON : -$167.30M

Returns By Period

In the year-to-date period, RAPT achieves a 71.30% return, which is significantly higher than CGON's 63.01% return.

RAPT

• 1D: 0.00%
• 1M: 0.07%
• YTD: 71.30%
• 6M: 124.97%
• 1Y: 494.47%
• 3Y*: -38.25%
• 5Y*: -15.58%
• 10Y*: —

CGON

• 1D: 5.82%
• 1M: 15.10%
• YTD: 63.01%
• 6M: 68.02%
• 1Y: 176.36%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RAPT vs. CGON — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RAPT

RAPT Risk / Return Rank: 98
RAPT Sharpe Ratio Rank: 99
RAPT Sortino Ratio Rank: 98
RAPT Omega Ratio Rank: 97
RAPT Calmar Ratio Rank: 99
RAPT Martin Ratio Rank: 98

CGON

CGON Risk / Return Rank: 92
CGON Sharpe Ratio Rank: 94
CGON Sortino Ratio Rank: 91
CGON Omega Ratio Rank: 91
CGON Calmar Ratio Rank: 91
CGON Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RAPT vs. CGON - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for RAPT Therapeutics, Inc. (RAPT) and CG Oncology, Inc (CGON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RAPT	CGON	Difference
Sharpe ratio Return per unit of total volatility	4.73	2.50	+2.23
Sortino ratio Return per unit of downside risk	4.47	3.00	+1.47
Omega ratio Gain probability vs. loss probability	1.59	1.42	+0.17
Calmar ratio Return relative to maximum drawdown	11.35	4.30	+7.05
Martin ratio Return relative to average drawdown	25.83	15.60	+10.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RAPT vs. CGON - Sharpe Ratio Comparison

The current RAPT Sharpe Ratio is 4.73, which is higher than the CGON Sharpe Ratio of 2.50. The chart below compares the historical Sharpe Ratios of RAPT and CGON, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RAPT	CGON	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	4.73	2.50	+2.23
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.13	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.49	-0.56

Correlation

The correlation between RAPT and CGON is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RAPT vs. CGON - Dividend Comparison

Neither RAPT nor CGON has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RAPT vs. CGON - Drawdown Comparison

The maximum RAPT drawdown since its inception was -98.47%, which is greater than CGON's maximum drawdown of -67.47%. Use the drawdown chart below to compare losses from any high point for RAPT and CGON.

Drawdown Indicators

	RAPT	CGON	Difference
Max Drawdown Largest peak-to-trough decline	-98.47%	-67.47%	-31.00%
Max Drawdown (1Y) Largest decline over 1 year	-36.08%	-29.90%	-6.18%
Max Drawdown (5Y) Largest decline over 5 years	-98.14%	—	—
Current Drawdown Current decline from peak	-85.16%	-1.40%	-83.76%
Average Drawdown Average peak-to-trough decline	-63.85%	-27.36%	-36.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.87%	10.01%	+12.86%

Volatility

RAPT vs. CGON - Volatility Comparison

The current volatility for RAPT Therapeutics, Inc. (RAPT) is 0.51%, while CG Oncology, Inc (CGON) has a volatility of 13.55%. This indicates that RAPT experiences smaller price fluctuations and is considered to be less risky than CGON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RAPT	CGON	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.51%	13.55%	-13.04%
Volatility (6M) Calculated over the trailing 6-month period	69.27%	42.77%	+26.50%
Volatility (1Y) Calculated over the trailing 1-year period	119.45%	71.55%	+47.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	123.30%	65.29%	+58.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	124.92%	65.29%	+59.63%

Financials